30 results on '"Gargiulo, Miriam"'
Search Results
2. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis
- Author
-
Sebastiani, Marco, Atzeni, Fabiola, Milazzo, Laura, Quartuccio, Luca, Scirè, Carlo, Gaeta, Giovanni Battista, Lapadula, Giovanni, Armignacco, Orlando, Tavio, Marcello, Olivieri, Ignazio, Meroni, Pierluigi, Bazzichi, Laura, Grassi, Walter, Mathieu, Alessandro, Mastroianni, Claudio, Sagnelli, Evangelista, Santantonio, Teresa, Uberti Foppa, Caterina, Puoti, Massimo, Sarmati, Loredana, Airò, Paolo, Epis, Oscar Massimiliano, Scrivo, Rossana, Gargiulo, Miriam, Riva, Agostino, Manfredi, Andreina, Ciancio, Giovanni, Zehender, Gianguglielmo, Taliani, Gloria, Meroni, Luca, Sollima, Salvatore, Sarzi-Puttini, Piercarlo, and Galli, Massimo
- Published
- 2017
- Full Text
- View/download PDF
3. Rapid progression of carotid lesions in HAART-treated HIV-1 patients
- Author
-
Maggi, Paolo, Perilli, Francesco, Lillo, Antonio, Gargiulo, Miriam, Ferraro, Sergio, Grisorio, Benvenuto, Ferrara, Sergio, Carito, Valentina, Bellacosa, Chiara, Pastore, Giuseppe, Chirianni, Antonio, and Regina, Guido
- Published
- 2007
- Full Text
- View/download PDF
4. CHEMOTHERAPY OF ADVANCED LIVER CANCER: A NOVEL THERAPEUTIC REGIMEN WITH PEGYLATED LYPOSOMAL DOXORUBICIN AND FOLINIC ACID MODULATED 5-FLUOROURACIL
- Author
-
Montesarchio, Vincenzo, Parrella, Roberto, Gargiulo, Miriam, Loiacono, Laura, Tarantino, Luciano, and Chirianni, Antonio
- Published
- 2003
5. Premature vascular lesions in HIV-positive patients: a clockwork bomb that will explode?
- Author
-
Maggi, Paolo, Fiorentino, Giuseppe, Epifani, Giuseppe, Ladisa, Nicoletta, Lillo, Antonio, Perilli, Francesco, Impedovo, Giovanni, Ferraro, Sergio, Gargiulo, Miriam, Angarano, Gioacchino, Chirianni, Antonio, and Pastore, Giuseppe
- Published
- 2002
6. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors
- Author
-
Maggi, Paolo, Serio, Gabriella, Epifani, Giuseppe, Fiorentino, Giuseppe, Saracino, Annalisa, Fico, Cecilia, Perilli, Francesco, Lillo, Antonio, Ferraro, Sergio, Gargiulo, Miriam, Chirianni, Antonio, Angarano, Gioacchino, Regina, Guido, and Pastore, Giuseppe
- Published
- 2000
7. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis
- Author
-
Sebastiani, Marco, primary, Milazzo, Laura, additional, Atzeni, Fabiola, additional, Vacchi, Caterina, additional, Manfredi, Andreina, additional, Quartuccio, Luca, additional, Scirè, Carlo, additional, Gaeta, Giovanni Battista, additional, Lapadula, Giovanni, additional, Armignacco, Orlando, additional, Tavio, Marcello, additional, D’Angelo, Salvatore, additional, Meroni, Pierluigi, additional, Bazzichi, Laura, additional, Grassi, Walter, additional, Mathieu, Alessandro, additional, Mastroianni, Claudio, additional, Sagnelli, Evangelista, additional, Santantonio, Teresa, additional, Foppa, Caterina Uberti, additional, Puoti, Massimo, additional, Sarmati, Loredana, additional, Airò, Paolo, additional, Epis, Oscar Massimiliano, additional, Scrivo, Rossana, additional, Gargiulo, Miriam, additional, Riva, Agostino, additional, Ciancio, Giovanni, additional, Zehender, Gianguglielmo, additional, Taliani, Gloria, additional, Meroni, Luca, additional, Sollima, Salvatore, additional, Sarzi-Puttini, Piercarlo, additional, and Galli, Massimo, additional
- Published
- 2019
- Full Text
- View/download PDF
8. Inconsistent condom use among HIV-positive women in the 'treatment as prevention era': data from the Italian DIDI study
- Author
-
Cicconi, Paola, Monforte, Antonella d'Arminio, Castagna, Antonella, Quirino, Tiziana, Alessandrini, Anna, Gargiulo, Miriam, Francisci, Daniela, Anzalone, Enza, Liuzzi, Giuseppina, Pierro, Paola, and Ammassari, Adriana
- Subjects
Condoms -- Research -- Usage ,HIV patients -- Surveys -- Beliefs, opinions and attitudes ,Health - Abstract
Introduction: Translation of the evidence regarding the protective role of highly active antiretroviral therapy (HAART) on HIV sexual transmission rates into sexual behaviour patterns of HIV-infected subjects remains largely unexplored. This study aims to describe frequency of self-reported condom use among women living with HIV in Italy and to investigate the variables associated with inconsistent condom use (ICU). Methods: DIDI (Donne con Infezione Da HIV) is an Italian multicentre study based on a questionnaire survey performed during November 2010 and February 2011. Women-reported frequency of condom use was dichotomized in 'always' versus 'at times'/'never' (ICU). Results: Among 343 women, prevalence of ICU was 44.3%. Women declared a stable partnership with an HIV-negative (38%) and with an HIV-positive person (43%), or an occasional sexual partner (19%). Among the 194 women engaged in a stable HIV-negative or an occasional partnership, 51% reported fear of infecting the partner. Nonetheless, 43% did not disclose HIV-positive status. Less than 5% of women used contraceptive methods other than condoms. At multivariable analysis, variables associated with ICU in the subgroup of women with a stable HIV-negative or an occasional HIV-unknown partner were: having an occasional partner (AOR 3.51, 95% confidence interval [CI] 1.44-8.54, p = 0.005), and reporting fear of infecting the sexual partner (AOR 3.20, 95% CI 1.43-7.16, p = 0.004). Current use of HAART together with virological control in plasma level did not predict ICU after adjusting for demographic, behavioural and HIV-related factors. With regard to socio-demographic factors, lower education was the only variable significantly associated with ICU in the multivariate analysis (AOR 2.27, 95% CI 1.07-4.82, p = 0.03). No association was found between high adherence to HAART and ICU after adjusting for potential confounders (AOR 0.89, 95% CI 0.39-2.01, p = 0.78). Conclusions: Currently in Italy, the use of HAART with undetectable HIV RNA in plasma as well as antiretroviral adherence is not associated with a specific condom use pattern in women living with HIV and engaged with a sero-discordant or an HIV-unknown partner. This might suggest that the awareness of the protective role of antiretroviral treatment on HIV sexual transmission is still limited among HIV-infected persons, at least in this country. Keywords: HIV; women; condom use; antiviral therapy; adherence., Introduction Intense interest has developed in the use of highly active antiretroviral therapy (HAART) to prevent HIV transmission. Indeed, the belief in the power of HIV suppression to stop secondary [...]
- Published
- 2013
- Full Text
- View/download PDF
9. Novel antiretroviral drugs and renal function monitoring of HIV patients
- Author
-
Maggi, P, Montinaro, V, Mussini, C, Di Biagio, A, Bellagamba, R, Bonfanti, P, Calza, L, Cherubini, C, Corsi, P, Gargiulo, M, Montella, F, Rusconi, S, Maggi, Paolo, Montinaro, Vincenzo, Mussini, Cristina, Di Biagio, Antonio, Bellagamba, Rita, Bonfanti, Paolo, Calza, Leonardo, Cherubini, Chiara, Corsi, Paola, Gargiulo, Miriam, Montella, Francesco, Rusconi, Stefano, Maggi, P, Montinaro, V, Mussini, C, Di Biagio, A, Bellagamba, R, Bonfanti, P, Calza, L, Cherubini, C, Corsi, P, Gargiulo, M, Montella, F, Rusconi, S, Maggi, Paolo, Montinaro, Vincenzo, Mussini, Cristina, Di Biagio, Antonio, Bellagamba, Rita, Bonfanti, Paolo, Calza, Leonardo, Cherubini, Chiara, Corsi, Paola, Gargiulo, Miriam, Montella, Francesco, and Rusconi, Stefano
- Abstract
Chronic kidney disease is a major comorbidity in patients affected by HIV infection. In addition, the introduction of new antiretroviral agents that interact with creatinine transporters is raising some concerns. In this review we analyze the currently available data about three new antiretroviral drugs and one new pharmacokinetic enhancer. Three of them (rilpivirine, cobicistat, dolutegravir) have shown some interactions with renal function, while tenofovir alafenamide fumarate reduces the plasmatic concentration of the parent drug. The future use of tenofovir alafenamide seems to be encouraging in order to reduce the renal interaction of tenofovir. Rilpivirine, cobicistat, and dolutegravir reduce the tubular secretion of creatinine, inducing a decrease of estimated glomerular filtration rate according to creatinine. Rilpivirine and dolutegravir block the uptake of creatinine from the blood, inhibiting organic cation transporter 2, and cobicistat interacts with the efflux inhibiting multidrug and toxin extrusion protein 1. This effect can then be considered a "reset" of the estimated glomerular filtration rate according to creatinine. However, clinicians should carefully monitor renal function in order to identify possible alterations suggestive of a true renal functional impairment. Owing to the interference of these drugs with creatinine secretion, an alternative way of estimation of glomerular filtration rate would be desirable. However, at the moment, other methods of direct glomerular filtration rate measurement have a high impact on the patient, are not readily available, or are not reliable in HIV patients. Consequently, use of classic formulas to estimate glomerular filtration rate is still recommended. Also, tubular function needs to be carefully monitored with simple tests such as proteinuria, phosphatemia, urinary excretion of phosphate, normoglycemic glycosuria, and excretion of uric acid.
- Published
- 2014
10. BRAVISSIMO: 12-month results from a large scale prospective trial.
- Author
-
Bosiers, M, Deloose, K, Callaert, Julie, Maene, L, Beelen, R, Keirse, Marc M.J.N.C., Verbist, J., Peeters, P, Schroë, H, Lauwers, G, Lansink, W, Vanslembroeck, K, D'archambeau, O, Hendriks, John, Lauwers, P, Vermassen, Frank, Randon, Caren, Van Herzeele, I, De Ryck, Frederic F.D., De Letter, J, Lanckneus, M, Van Betsbrugge, M, Thomas, B, Deleersnijder, R, Vandekerkhof, J, Baeyens, I, Berghmans, Thierry, Buttiens, J, Van Den Brande, Paul, Debing, Erik, Rabbia, C, Ruffino, A, Tealdi, D, Nano, G, Stegher, S, Gasparini, D, Piccoli, G, Coppieters De Gibson, Arnold G., Silingardi, R, Cataldi, V, Paroni, G, Palazzo, V, Stella, A, Gargiulo, Miriam, Muccini, N, Nessi, F, Ferrero, E, Pratesi, C, Fargion, A, Chiesa, R, Marone, E, Bertoglio, L, Cremonesi, A, Dozza, L, Galzerano, G, De Donato, G, Setacci, C., Bosiers, M, Deloose, K, Callaert, Julie, Maene, L, Beelen, R, Keirse, Marc M.J.N.C., Verbist, J., Peeters, P, Schroë, H, Lauwers, G, Lansink, W, Vanslembroeck, K, D'archambeau, O, Hendriks, John, Lauwers, P, Vermassen, Frank, Randon, Caren, Van Herzeele, I, De Ryck, Frederic F.D., De Letter, J, Lanckneus, M, Van Betsbrugge, M, Thomas, B, Deleersnijder, R, Vandekerkhof, J, Baeyens, I, Berghmans, Thierry, Buttiens, J, Van Den Brande, Paul, Debing, Erik, Rabbia, C, Ruffino, A, Tealdi, D, Nano, G, Stegher, S, Gasparini, D, Piccoli, G, Coppieters De Gibson, Arnold G., Silingardi, R, Cataldi, V, Paroni, G, Palazzo, V, Stella, A, Gargiulo, Miriam, Muccini, N, Nessi, F, Ferrero, E, Pratesi, C, Fargion, A, Chiesa, R, Marone, E, Bertoglio, L, Cremonesi, A, Dozza, L, Galzerano, G, De Donato, G, and Setacci, C.
- Abstract
The BRAVISSIMO study is a prospective, non-randomized, multi-center, multi-national, monitored trial, conducted at 12 hospitals in Belgium and 11 hospitals in Italy. This manuscript reports the findings up to the 12-month follow-up time point for both the TASC A&B cohort and the TASC C&D cohort. The primary endpoint of the study is primary patency at 12 months, defined as a target lesion without a hemodynamically significant stenosis on Duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR) within 12 months. Between July 2009 and September 2010, 190 patients with TASC A or TASC B aortoiliac lesions and 135 patients with TASC C or TASC D aortoiliac lesions were included. The demographic data were comparable for the TASC A/B cohort and the TASC C/D cohort. The number of claudicants was significantly higher in the TASC A/B cohort, The TASC C/D cohort contains more CLI patients. The primary patency rate for the total patient population was 93.1%. The primary patency rates at 12 months for the TASC A, B, C and D lesions were 94.0%, 96.5%, 91.3% and 90.2% respectively. No statistical significant difference was shown when comparing these groups. Our findings confirm that endovascular therapy, and more specifically primary stenting, is the preferred treatment for patients with TASC A, B, C and D aortoiliac lesions. We notice similar endovascular results compared to surgery, however without the invasive character of surgery., info:eu-repo/semantics/published
- Published
- 2013
11. Trastuzumab resistance: Bringing tailored therapy to the clinic
- Author
-
Bannister, Wendy, Ruiz, Lidia, Cozzi-Lepri, Alessandro, Mocroft, Amanda, Kirk, Ole, Staszewski, Schlomo, Loveday, Clive, Karlsson, Anders, d'Arminio Monforte, Antonella, Clotet, Bonaventura, Lundgren, Jens D, Losso, Marcello, Durand, Arnaud, Vetter, Norbert, Karpov, Igor, Vassilenko, A., Clumeck, Nathan, Dewit, Suzanne, Poll, Bénédicte, Colebunders, Robert Leon, Kostov, Kostadin, Begovac, Josip, Ristola, Matti, Machala, Ladislav, Rozsypal, Hanuš, Sedlacek, Dalibor, Nielsen, Jorgen E, Benfield, Thomas, Gerstoft, Jan, Katzenstein, Terese Lea, Hansen, Annette Brit Eg, Skinhøj, Peter, Pedersen, Court, Oestergaard, Lone Lange, Zilmer, Kai, Smidt, Jelena, Katlama, Christine, Viard, Jean-Paul, Girard, Pierre Marie, Livrozet, Jean-Michel, Vanhems, Philippe, Pradier, Christian, Dabis, François, Rockstroh, Jürgen, Schmidt, Rüdiger, Van Lunzen, Jan, Degen, Olaf, Stellbrink, Hans-Jurgen, Bogner, Johannes, Fätkenheuer, Gerd, Kosmidis, John, Gargalianos, Panagiotis, Xylomenos, George, Perdios, J., Panos, George, Filandras, A., Karabatsaki, E., Sambattakou, H., Banhegyi, Dénes, Mulcahy, Fiona, Yust, Israel, Turner, Dan, Burke, Michael, Pollack, Simeon, Hassoun, Gamal, Maayan, Shlomo, Chiesi, Antonio, Esposito, Roberto, Mazeu, I., Mussini, Cirillo, Arici, Claudio, Pristera, Raffaele, Mazzotta, Francesco, Gabbuti, Andrea, Vullo, Vincenzo, Lichtner, Miriam, Chirianni, Antonio, Montesarchio, Enzo, Gargiulo, Miriam, Antonucci, Giorgio, Iacomi, Fabio, Narciso, Pasquale, Vlassi, Chrysoula, Zaccarelli, Mauro, Lazzarin, Adriano, Finazzi, Renato, Galli, Mara, Ridolfo, Anna Lisa, Rozentale, Baiba, Aldins, Pauls, Chaplinskas, Saulius, Hemmer, Robert, Staub, Thérèse, Reiss, Peter, Bruun, Johan, Maeland, Arild, Ormaasen, Vidar, Knysz, Brygida, Gasiorowski, Jacek, Horban, Andrzej, Prokopowicz, Danuta, Wiercinska-Drapalo, A., Boron-Kaczmarska, Anna, Pynka, Magdalena, Beniowski, Marek, Mularska, Elzbieta, Trocha, Hanna, Antunes, Francisco, Valadas, Emília, Mansinho, Kamal, Maltez, Fernando, Duiculescu, Dan, Rakhmanova, Aza, Vinogradova, E., Buzunova, S., Jevtovic, Djordje, Mokráš, Miloš, Staneková, Danica, Gonzalez-Lahoz, Juan, Soriano, V., Martin-Carbonero, L., Labarga, P., Jou, A., Conejero, J., Tural, C., Gatell, J.M., Miró, José María, Domingo, Perre, Gutierrez, Maria, Mateo, V, Sambeat, María Antònia, Karlsson, Annika, Persson, P.O., Flamholc, Leo, Ledergerber, Bruno, Weber, R., Francioli, Patrick, Cavassini, Matthias, Hirschel, Bernard, Boffi, Emmanuelle, Furrer, Hansjakob, Battegay, Manuel, Elzi, Luigia, Kravchenko, É V., Chentsova, Nelly, Barton, Simon E.Simon, Johnson, Antoinette, Mercey, Danielle, Phillips, Adam, Johnson, Margaret, Murphy, M., Weber, J., Scullard, George, Fisher, Martin, Brettle, R., Antunes, F., Gatell, Jose, Gazzard, Brian George, Ledergerber, B., Reiss, P., Friis-Møller, Nina, Cozzi-Lepri, A., Bannister, W., Ellefson, M., Borch, A., Podlevkareva, D., Holkmann Olsen, C., Kjar, J., Petersen, Lars, Reekie, J., Bannister, Wendy, Ruiz, Lidia, Cozzi-Lepri, Alessandro, Mocroft, Amanda, Kirk, Ole, Staszewski, Schlomo, Loveday, Clive, Karlsson, Anders, d'Arminio Monforte, Antonella, Clotet, Bonaventura, Lundgren, Jens D, Losso, Marcello, Durand, Arnaud, Vetter, Norbert, Karpov, Igor, Vassilenko, A., Clumeck, Nathan, Dewit, Suzanne, Poll, Bénédicte, Colebunders, Robert Leon, Kostov, Kostadin, Begovac, Josip, Ristola, Matti, Machala, Ladislav, Rozsypal, Hanuš, Sedlacek, Dalibor, Nielsen, Jorgen E, Benfield, Thomas, Gerstoft, Jan, Katzenstein, Terese Lea, Hansen, Annette Brit Eg, Skinhøj, Peter, Pedersen, Court, Oestergaard, Lone Lange, Zilmer, Kai, Smidt, Jelena, Katlama, Christine, Viard, Jean-Paul, Girard, Pierre Marie, Livrozet, Jean-Michel, Vanhems, Philippe, Pradier, Christian, Dabis, François, Rockstroh, Jürgen, Schmidt, Rüdiger, Van Lunzen, Jan, Degen, Olaf, Stellbrink, Hans-Jurgen, Bogner, Johannes, Fätkenheuer, Gerd, Kosmidis, John, Gargalianos, Panagiotis, Xylomenos, George, Perdios, J., Panos, George, Filandras, A., Karabatsaki, E., Sambattakou, H., Banhegyi, Dénes, Mulcahy, Fiona, Yust, Israel, Turner, Dan, Burke, Michael, Pollack, Simeon, Hassoun, Gamal, Maayan, Shlomo, Chiesi, Antonio, Esposito, Roberto, Mazeu, I., Mussini, Cirillo, Arici, Claudio, Pristera, Raffaele, Mazzotta, Francesco, Gabbuti, Andrea, Vullo, Vincenzo, Lichtner, Miriam, Chirianni, Antonio, Montesarchio, Enzo, Gargiulo, Miriam, Antonucci, Giorgio, Iacomi, Fabio, Narciso, Pasquale, Vlassi, Chrysoula, Zaccarelli, Mauro, Lazzarin, Adriano, Finazzi, Renato, Galli, Mara, Ridolfo, Anna Lisa, Rozentale, Baiba, Aldins, Pauls, Chaplinskas, Saulius, Hemmer, Robert, Staub, Thérèse, Reiss, Peter, Bruun, Johan, Maeland, Arild, Ormaasen, Vidar, Knysz, Brygida, Gasiorowski, Jacek, Horban, Andrzej, Prokopowicz, Danuta, Wiercinska-Drapalo, A., Boron-Kaczmarska, Anna, Pynka, Magdalena, Beniowski, Marek, Mularska, Elzbieta, Trocha, Hanna, Antunes, Francisco, Valadas, Emília, Mansinho, Kamal, Maltez, Fernando, Duiculescu, Dan, Rakhmanova, Aza, Vinogradova, E., Buzunova, S., Jevtovic, Djordje, Mokráš, Miloš, Staneková, Danica, Gonzalez-Lahoz, Juan, Soriano, V., Martin-Carbonero, L., Labarga, P., Jou, A., Conejero, J., Tural, C., Gatell, J.M., Miró, José María, Domingo, Perre, Gutierrez, Maria, Mateo, V, Sambeat, María Antònia, Karlsson, Annika, Persson, P.O., Flamholc, Leo, Ledergerber, Bruno, Weber, R., Francioli, Patrick, Cavassini, Matthias, Hirschel, Bernard, Boffi, Emmanuelle, Furrer, Hansjakob, Battegay, Manuel, Elzi, Luigia, Kravchenko, É V., Chentsova, Nelly, Barton, Simon E.Simon, Johnson, Antoinette, Mercey, Danielle, Phillips, Adam, Johnson, Margaret, Murphy, M., Weber, J., Scullard, George, Fisher, Martin, Brettle, R., Antunes, F., Gatell, Jose, Gazzard, Brian George, Ledergerber, B., Reiss, P., Friis-Møller, Nina, Cozzi-Lepri, A., Bannister, W., Ellefson, M., Borch, A., Podlevkareva, D., Holkmann Olsen, C., Kjar, J., Petersen, Lars, and Reekie, J.
- Abstract
SCOPUS: re.j, info:eu-repo/semantics/published
- Published
- 2008
12. Role of FAP48 in HIV‐associated lipodystrophy
- Author
-
Esposito, Vincenzo, primary, Manente, Lucrezia, additional, Lucariello, Angela, additional, Perna, Angelica, additional, Viglietti, Rosaria, additional, Gargiulo, Miriam, additional, Parrella, Roberto, additional, Parrella, Giovanni, additional, Baldi, Alfonso, additional, De Luca, Antonio, additional, and Chirianni, Antonio, additional
- Published
- 2012
- Full Text
- View/download PDF
13. Novel Antiretroviral Drugs and Renal Function Monitoring of HIV Patients.
- Author
-
Maggi, Paolo, Montinaro, Vincenzo, Mussini, Cristina, Di Biagio, Antonio, Bellagamba, Rita, Bonfanti, Paolo, Calza, Leonardo, Cherubini, Chiara, Corsi, Paola, Gargiulo, Miriam, Montella, Francesco, and Rusconi, Stefano
- Abstract
Chronic kidney disease is a major comorbidity in patients affected by HIV infection. In addition, the introduction of new antiretroviral agents that interact with creatinine transporters is raising some concerns. In this review we analyze the currently available data about three new antiretroviral drugs and one new pharmacokinetic enhancer. Three of them (rilpivirine, cobicistat, dolutegravir) have shown some interactions with renal function, while tenofovir alafenamide fumarate reduces the plasmatic concentration of the parent drug. The future use of tenofovir alafenamide seems to be encouraging in order to reduce the renal interaction of tenofovir. Rilpivirine, cobicistat, and dolutegravir reduce the tubular secretion of creatinine, inducing a decrease of estimated glomerular filtration rate according to creatinine. Rilpivirine and dolutegravir block the uptake of creatinine from the blood, inhibiting organic cation transporter 2, and cobicistat interacts with the efflux inhibiting multidrug and toxin extrusion protein 1. This effect can then be considered a “reset” of the estimated glomerular filtration rate according to creatinine. However, clinicians should carefully monitor renal function in order to identify possible alterations suggestive of a true renal functional impairment. Owing to the interference of these drugs with creatinine secretion, an alternative way of estimation of glomerular filtration rate would be desirable. However, at the moment, other methods of direct glomerular filtration rate measurement have a high impact on the patient, are not readily available, or are not reliable in HIV patients. Consequently, use of classic formulas to estimate glomerular filtration rate is still recommended. Also, tubular function needs to be carefully monitored with simple tests such as proteinuria, phosphatemia, urinary excretion of phosphate, normoglycemic glycosuria, and excretion of uric acid. [ABSTRACT FROM AUTHOR]
- Published
- 2014
14. Septic shock from Eikenella corrodens and Staphylococcus epidermidis in HIV infection
- Author
-
Gargiulo, Miriam, primary, Gramenzi, Annagiulia, additional, Ottavio, LiciaDi, additional, Gandolfi, Paola, additional, and Manso, Esther, additional
- Published
- 1992
- Full Text
- View/download PDF
15. Open Randomized Controlled Parallel Study of Ofloxacin versus Trimethoprim-Sulfamethoxazole Treatment of Lower Respiratory Tract and Urinary Infections
- Author
-
De Simone, Claudio, primary, Di Fabio, Simonetta, additional, Moretti, Sonia, additional, Tzantzoglou, Sonia, additional, Trinchieri, Vito, additional, and Gargiulo, Miriam, additional
- Published
- 1991
- Full Text
- View/download PDF
16. Application of a high-performance liquid chromatography coulometric method for the estimation of mebendazole and its metabolites in human sera
- Author
-
Betto, Peppino, primary, Gianbenedetti, Massimo, additional, Ponti, Fernando, additional, Ferretti, Rosella, additional, Settimj, Guido, additional, Gargiulo, Miriam, additional, and Lorenzini, Rodolfo, additional
- Published
- 1991
- Full Text
- View/download PDF
17. Role of NEDD8 in HIV-associated lipodystrophy
- Author
-
Esposito, Vincenzo, Manente, Lucrezia, Perna, Angelica, Gargiulo, Miriam, Viglietti, Rosaria, Sangiovanni, Vincenzo, Doula, Nectaria, Liuzzi, Giuseppina, Baldi, Alfonso, De Luca, Antonio, and Chirianni, Antonio
- Abstract
The pathogenetic bases of HAART-associated lipodystrophy are still poorly known, even if it is clear that adipose tissue and its metabolism are sensitive to antiretroviral therapy alone and/or in combination with HIV infection. The NEDD8 system is essential for the regulation of protein degradation pathways involved in cell cycle progression, morphogenesis and tumorigenesis. We investigated the possible involvement of NEED8 in adipogenesis and, consequently, in HIV-related lipodystrophy.
- Published
- 2009
- Full Text
- View/download PDF
18. Adventitial Microcirculation Is a Major Target of SARS-CoV-2-Mediated Vascular Inflammation
- Author
-
Francesco Vasuri, Gianandrea Pasquinelli, Alessio Degiovanni, Miriam Capri, Mauro Gargiulo, Carmen Ciavarella, Salvatore Collura, Sabrina Valente, Chiara Mascoli, and Francesco Vasuri, Carmen Ciavarella, Salvatore Collura, Chiara Mascoli, Sabrina Valente, Alessio Degiovanni, Mauro Gargiulo, Miriam Capri, Gianandrea Pasquinelli
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,SARS- CoV-2 ,Inflammation ,Case Report ,030204 cardiovascular system & hematology ,medicine.disease_cause ,Biochemistry ,Microbiology ,artery disease ,Microcirculation ,03 medical and health sciences ,0302 clinical medicine ,transmission electron microscopy ,medicine ,Receptor ,Interleukin 6 ,Molecular Biology ,Coronavirus ,miRNA ,IL-6 ,biology ,business.industry ,SARS-CoV-2 ,COVID-19 ,QR1-502 ,030104 developmental biology ,medicine.anatomical_structure ,inflammation ,Vasa vasorum ,immunohistochemistry ,biology.protein ,Immunohistochemistry ,medicine.symptom ,business ,Artery - Abstract
We report the case of a 77-year-old woman affected by coronavirus disease-19 (COVID-19) who developed an occlusive arterial disease of the lower limb requiring a left leg amputation. We studied the mechanisms of vascular damage by SARS-CoV-2 by means of a comprehensive multi-technique in situ analysis on the diseased popliteal arterial district, including immunohistochemistry (IHC), transmission electron microscopy (TEM) and miRNA analysis. At histological analyses, we observed a lymphocytic inflammatory infiltrate, oedema and endothelialitis of adventitial vasa vasorum while the media was normal and the intima had only minor changes. The vasa vasorum expressed the ACE2 receptor and factor VIII; compared with the controls, VEGFR2 staining was reduced. TEM analyses showed endothelial injury and numerous Weibel–Palade bodies in the cytoplasm. No coronavirus particle was seen. IL-6 protein and mRNA, together with miR-155-5p and miRs-27a-5p, which can target IL-6, were significantly increased compared with that in the controls. Our case report suggests an involvement of adventitial artery microcirculation by inflammation in the course of COVID-19. Without evident signs of current infection by SARS-CoV-2, endothelial cells show a spectrum of structural and functional alterations that can fuel the cardiovascular complications observed in people infected with SARS-CoV-2.
- Published
- 2021
19. The carotid plaque as paradigmatic case of site-specific acceleration of aging process: The microRNAs and the inflammaging contribution
- Author
-
Antonia D'Errico, Mauro Gargiulo, Sara Fronterrè, Salvatore Collura, Claudio Franceschi, Francesco Vasuri, Carmen Ciavarella, Miriam Capri, Gianandrea Pasquinelli, Andrea Vacirca, Cristina Morsiani, and Salvatore Collura, Cristina Morsiani, Andrea Vacirca, Sara Fronterrè, Carmen Ciavarella, Francesco Vasuri, Antonia D'Errico, Claudio Franceschi, Gianandrea Pasquinelli, Mauro Gargiulo, Miriam Capri
- Subjects
0301 basic medicine ,Carotid Artery Diseases ,Aging ,medicine.medical_treatment ,Population ,Acceleration ,Chronic inflammatory disease ,Bioinformatics ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,microRNA ,Medicine ,Humans ,microRNAs ,education ,Molecular Biology ,Stroke ,Endarterectomy ,Plaque ,Aged, 80 and over ,education.field_of_study ,Geroscience ,business.industry ,Biomarker ,medicine.disease ,Inflammaging ,Plaque, Atherosclerotic ,MicroRNAs ,030104 developmental biology ,Atheroma ,Neurology ,Artery diseases ,business ,030217 neurology & neurosurgery ,Carotid artery ,Biotechnology - Abstract
Atherosclerosis is considered a chronic inflammatory disease of arteries associated with the aging process. Many risk factors have been identified and they are mainly related to life-styles, gene-environment interactions and socioeconomic status. Carotid and coronary artery diseases are the two major atherosclerotic conditions, being the primary cause of stroke and heart attack, respectively. Nevertheless, carotid plaque assumes particular aspects not only for the specific molecular mechanisms, but also for the types of atheroma which may be associated with a better or a worst prognosis. The identification of circulating blood biomarkers able to distinguish carotid plaque types (stable or vulnerable) is a crucial step for the improvement of adequate therapeutic approaches avoiding or delaying endarterectomy in the oldest old individuals (> 80 years), a population predicted to growth in the next years. The review highlights the most recent knowledge on carotid plaque molecular mechanisms, focusing on microRNAs (miRs), as a site-specific accelerated aging within the conceptual framework of Geroscience for new affordable therapies.
- Published
- 2020
20. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis
- Author
-
Massimo Galli, Evangelista Sagnelli, Luca Meroni, Pier Luigi Meroni, Massimo Puoti, Paolo Airò, Giovanni Battista Gaeta, Carlo Alberto Scirè, Gloria Taliani, M. Gargiulo, Laura Milazzo, Salvatore Sollima, Teresa Santantonio, Alessandro Mathieu, Marco Sebastiani, Andreina Teresa Manfredi, Agostino Riva, Gianguglielmo Zehender, Caterina Uberti Foppa, Orlando Armignacco, Giovanni Lapadula, Laura Bazzichi, Claudio Maria Mastroianni, Oscar Massimiliano Epis, Luca Quartuccio, Loredana Sarmati, Marcello Tavio, Fabiola Atzeni, Ignazio Olivieri, Piercarlo Sarzi-Puttini, Giovanni Ciancio, Rossana Scrivo, Walter Grassi, Sebastiani, M, Atzeni, F, Milazzo, L, Quartuccio, L, Scirè, C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, Olivieri, I, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airò, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Manfredi, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani, Marco, Atzeni, Fabiola, Milazzo, Laura, Quartuccio, Luca, Scirã, Carlo, Gaeta, Giovanni Battista, Lapadula, Giovanni, Armignacco, Orlando, Tavio, Marcello, Olivieri, Ignazio, Meroni, Pierluigi, Bazzichi, Laura, Grassi, Walter, Mathieu, Alessandro, Mastroianni, Claudio, Sagnelli, Evangelista, Santantonio, Teresa, Uberti Foppa, Caterina, Puoti, Massimo, Sarmati, Loredana, Airã², Paolo, Epis, Oscar Massimiliano, Scrivo, Rossana, Gargiulo, Miriam, Riva, Agostino, Manfredi, Andreina, Ciancio, Giovanni, Zehender, Gianguglielmo, Taliani, Gloria, Meroni, Luca, Sollima, Salvatore, Sarzi-Puttini, Piercarlo, Galli, Massimo, Sebastiani, M., Atzeni, F., Milazzo, L., Quartuccio, L., Scire, C., Gaeta, G. B., Lapadula, G., Armignacco, O., Tavio, M., Olivieri, I., Meroni, P., Bazzichi, L., Grassi, W., Mathieu, A., Mastroianni, C., Sagnelli, E., Santantonio, T., Uberti Foppa, C., Puoti, M., Sarmati, L., Airo, P., Epis, O. M., Scrivo, R., Gargiulo, M., Riva, A., Manfredi, A., Ciancio, G., Zehender, G., Taliani, G., Meroni, L., Sollima, S., Sarzi-Puttini, P., Galli, M., UBERTI FOPPA, Caterina, and Sarzi puttini, Piercarlo
- Subjects
Male ,medicine.medical_specialty ,Settore MED/17 - Malattie Infettive ,Comorbidity ,Therapeutics ,medicine.disease_cause ,Antiviral Agents ,Risk Assessment ,Severity of Illness Index ,NO ,Arthritis, Rheumatoid ,03 medical and health sciences ,0302 clinical medicine ,Hepatitis B, Chronic ,Rheumatology ,Internal medicine ,Biologic DMARDs ,Hepatitis B ,Rheumatoid arthritis ,Medicine ,Humans ,In patient ,Infectious disease (athletes) ,Rheumatoid arthriti ,030203 arthritis & rheumatology ,Hepatitis B virus ,business.industry ,Biologic DMARD ,medicine.disease ,Prognosis ,Occult ,Vaccination ,Italy ,Immunology ,Practice Guidelines as Topic ,Rheumatoid arthritis, hepatitis B virus ,030211 gastroenterology & hepatology ,Female ,business ,hepatitis B virus - Abstract
Objectives Hepatitis B (HBV) infection, which is prevalent worldwide, is also frequently seen in patients with rheumatoid arthritis (RA). The Italian Society of Rheumatology (SIR) and the Italian Society of Infectious and Tropical Diseases (SIMIT) endorsed a national consensus process to review the available evidence on HBV management in RA patients and to produce practical, hospital-wide recommendations. Methods The consensus panel consisted of infectious disease consultants, rheumatologists and epidemiologists and used the criteria of the Oxford Center for Evidence-based Medicine to assess the quality of the evidence and the strength of their recommendations. Results A core-set of statements has been developed to help clinicians in the management of patients with RA and HBV infection. Vaccination and prophylaxis of RA patients treated with biological drugs have been also discussed. Conclusions HBV infection is not rare in clinical practice; a screening for HBV in all patients with early arthritis is not universally accepted, while it is considered mandatory before starting any immunosuppressive or hepatotoxic treatment. In fact, a specific risk, associated with the use of biologic treatments, exists for patients with HBV infection, although longitudinal studies of viral reactivation are generally reassuring. RA patients with HBV infection should be referred to the hepatologist and correctly classified into active or inactive carriers. Patients with active hepatitis B should undergo antiviral treatment before starting immunosuppressive treatments. Occult HBV carriers should be monitored or receive prophylaxis on the basis of the risk of reactivation associated with the administered treatment.
- Published
- 2017
21. Novel antiretroviral drugs and renal function monitoring of HIV patients
- Author
-
Maggi, P., vincenzo montinaro, Mussini, C., Di Biagio, A., Bellagamba, R., Bonfanti, P., Calza, L., Cherubini, C., Corsi, P., Gargiulo, M., Montella, F., Rusconi, S., Maggi, P, Montinaro, V, Mussini, C, Di Biagio, A, Bellagamba, R, Bonfanti, P, Calza, L, Cherubini, C, Corsi, P, Gargiulo, M, Montella, F, Rusconi, S., Rusconi, S, Maggi, Paolo, Montinaro, Vincenzo, Mussini, Cristina, Di Biagio, Antonio, Bellagamba, Rita, Bonfanti, Paolo, Calza, Leonardo, Cherubini, Chiara, Corsi, Paola, Gargiulo, Miriam, Montella, Francesco, and Rusconi, Stefano
- Subjects
kidney ,Monitoring ,Anti-HIV Agents ,Pyridones ,Oxazine ,Organophosphonates ,HIV Infections ,Pyridone ,3-Ring ,Kidney Function Tests ,Piperazines ,Heterocyclic Compounds ,Organophosphonate ,Nitriles ,Oxazines ,Humans ,renal function ,HIV Infection ,Physiologic ,Tenofovir ,Piperazine ,Monitoring, Physiologic ,Kidney Function Test ,new drug ,Adenine ,Rilpivirine ,Carbamates ,Cobicistat ,Heterocyclic Compounds, 3-Ring ,Pyrimidines ,Thiazoles ,Anti-HIV Agent ,Antiretroviral therapy ,Pyrimidine ,Carbamate ,Thiazole ,Nitrile ,Human - Abstract
Chronic kidney disease is a major comorbidity in patients affected by HIV infection. In addition, the introduction of new antiretroviral agents that interact with creatinine transporters is raising some concerns. In this review we analyze the currently available data about three new antiretroviral drugs and one new pharmacokinetic enhancer. Three of them (rilpivirine, cobicistat, dolutegravir) have shown some interactions with renal function, while tenofovir alafenamide fumarate reduces the plasmatic concentration of the parent drug. The future use of tenofovir alafenamide seems to be encouraging in order to reduce the renal interaction of tenofovir. Rilpivirine, cobicistat, and dolutegravir reduce the tubular secretion of creatinine, inducing a decrease of estimated glomerular filtration rate according to creatinine. Rilpivirine and dolutegravir block the uptake of creatinine from the blood, inhibiting organic cation transporter 2, and cobicistat interacts with the efflux inhibiting multidrug and toxin extrusion protein 1. This effect can then be considered a "reset" of the estimated glomerular filtration rate according to creatinine. However, clinicians should carefully monitor renal function in order to identify possible alterations suggestive of a true renal functional impairment. Owing to the interference of these drugs with creatinine secretion, an alternative way of estimation of glomerular filtration rate would be desirable. However, at the moment, other methods of direct glomerular filtration rate measurement have a high impact on the patient, are not readily available, or are not reliable in HIV patients. Consequently, use of classic formulas to estimate glomerular filtration rate is still recommended. Also, tubular function needs to be carefully monitored with simple tests such as proteinuria, phosphatemia, urinary excretion of phosphate, normoglycemic glycosuria, and excretion of uric acid.
- Published
- 2014
22. Inconsistent condom use among HIV-positive women in the ‘‘Treatment as Prevention Era’’: data from the Italian DIDI study
- Author
-
Cicconi, P, Monforte, Ad, Castagna, A, Quirino, T, Alessandrini, A, Gargiulo, M, Francisci, Daniela, Anzalone, E, Liuzzi, G, Pierro, P, Ammassari, A, DIDI Study Group, Cicconi, Paola, Monforte Antonella, D'Arminio, Castagna, Antonella, Quirino, Tiziana, Alessandrini, Anna, Gargiulo, Miriam, Francisci, Daniela, Anzalone, Enza, Liuzzi, Giuseppina, Pierro, Paola, and Ammassari, Adriana
- Subjects
Sexual partner ,Adult ,medicine.medical_specialty ,Multivariate analysis ,Sexual transmission ,Sexual Behavior ,HIV ,women ,condom use ,antiviral therapy ,adherence ,HIV Infections ,law.invention ,Condoms ,Condom ,Acquired immunodeficiency syndrome (AIDS) ,law ,Surveys and Questionnaires ,Medicine ,Humans ,Gynecology ,business.industry ,Confounding ,Public Health, Environmental and Occupational Health ,virus diseases ,Treatment as prevention ,medicine.disease ,Confidence interval ,Infectious Diseases ,Italy ,Female ,business ,Demography ,Research Article - Abstract
Introduction: Translation of the evidence regarding the protective role of highly active antiretroviral therapy (HAART) on HIV sexual transmission rates into sexual behaviour patterns of HIV-infected subjects remains largely unexplored. This study aims to describe frequency of self-reported condom use among women living with HIV in Italy and to investigate the variables associated with inconsistent condom use (ICU). Methods: DIDI (Donne con Infezione Da HIV) is an Italian multicentre study based on a questionnaire survey performed during November 2010 and February 2011. Women-reported frequency of condom use was dichotomized in ‘‘always’’ versus ‘‘at times’’/‘‘never’’ (ICU). Results: Among 343 women, prevalence of ICU was 44.3%.Women declared a stable partnership with an HIV-negative (38%) and with an HIV-positive person (43%), or an occasional sexual partner (19%). Among the 194 women engaged in a stable HIVnegative or an occasional partnership, 51% reported fear of infecting the partner. Nonetheless, 43% did not disclose HIV-positive status. Less than 5% of women used contraceptive methods other than condoms. At multivariable analysis, variables associated with ICU in the subgroup of women with a stable HIV-negative or an occasional HIV-unknown partner were: having an occasional partner (AOR 3.51, 95% confidence interval [CI] 1.44-8.54, p =0.005), and reporting fear of infecting the sexual partner (AOR 3.20, 95% CI 1.43-7.16, p =0.004). Current use of HAART together with virological control in plasma level did not predict ICU after adjusting for demographic, behavioural and HIV-related factors. With regard to socio-demographic factors, lower education was the only variable significantly associated with ICU in the multivariate analysis (AOR 2.27, 95% CI 1.07-4.82, p =0.03). No association was found between high adherence to HAART and ICU after adjusting for potential confounders (AOR 0.89, 95% CI 0.39-2.01, p =0.78). Conclusions: Currently in Italy, the use of HAART with undetectable HIV RNA in plasma as well as antiretroviral adherence is not associated with a specific condom use pattern in women living with HIV and engaged with a sero-discordant or an HIV-unknown partner. This might suggest that the awareness of the protective role of antiretroviral treatment on HIV sexual transmission is still limited among HIV-infected persons, at least in this country. Keywords: HIV; women; condom use; antiviral therapy; adherence. (Published: 17 October 2013) Citation: Cicconi P et al. Journal of the International AIDS Society 2013, 16 :18591 http://www.jiasociety.org/index.php/jias/article/view/18591 | http://dx.doi.org/10.7448/IAS.16.1.18591
- Published
- 2013
23. Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma.
- Author
-
Carleo MA, Di Martino F, Del Giudice A, Gargiulo M, Parrella G, Rosario P, Sangiovanni V, Viglietti R, Esposito V, and Chirianni A
- Subjects
- Adult, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, HIV Infections drug therapy, HIV Infections virology, HIV Protease Inhibitors therapeutic use, Humans, Male, Middle Aged, Risk Factors, Sarcoma, Kaposi drug therapy, Sarcoma, Kaposi pathology, Sarcoma, Kaposi prevention & control, Treatment Outcome, Viral Load, Young Adult, HIV Infections complications, HIV Protease Inhibitors pharmacology, Sarcoma, Kaposi etiology
- Abstract
Background: The incidence of Kaposi's sarcoma (KS), an AIDS-related malignancy, has dramatically decreased in the Highly Active Anti-retroviral Therapy (HAART) era. However, KS remains the second most frequent tumor in HIV-infected patients worldwide and has become the most common cancer in the sub-Saharan Africa. Experimental studies have demonstrated a direct anti-neoplastic effect of HAART, and overall of protease inhibitors (PIs), on KS., Case Report: We describe five cases of KS in HIV-infected patients on HAART regimen, containing PIs as atazanavir/r (ATV/r), darunavir/r (DRV/r), lopinavir/r (LPV/r) and fosamprenavir (fAMP/r)., Conclusion: Clinical and experimental observations support the hypothesis that PIs may play an important role in prevention and treatment of KS. In our study, the treatment with PIs of recent generation was not protective against the development of KS. Therefore, it could be necessary to re-evaluate the therapeutic effects of PIs and their role in the development and treatment of KS in HIV-infected patients., (Copyright © 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2015
24. Interferon gamma release assays and tubercolin skin test performance in different settings of HIV immunodeficiency.
- Author
-
Parrella R, Esposito V, Onofrio M, Parrella G, Viglietti R, Sangiovanni V, Gargiulo M, Di Martino F, Del Giudice A, Santoro G, Bernardo M, Carleo MA, and Chirianni A
- Subjects
- Adult, Aged, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Female, Humans, Male, Middle Aged, Reproducibility of Results, Sensitivity and Specificity, Viral Load, Young Adult, HIV Infections drug therapy, HIV Infections immunology, HIV Infections virology, Interferon-gamma Release Tests standards, Latent Tuberculosis diagnosis, Tuberculin Test standards
- Abstract
Background/aim: HIV infection is a risk factor for re-activation of latent tubercolosis infection (LTBI). In recent years new blood tests for the detection of TB infection have been developed: Quantiferon TB Gold in Tube and TSPOT TB, which are interferon-γ releasing assays (IGRAs), have improved the identification of LTBI. In our study we have compared IGRAs and TST in HIV-positive patients with different settings of immunodeficiency., Patients and Methods: 98 consecutive HIV patients were recruited. They underwent a blood draw, a chest radiography and a tuberculin skin test. The HIV infection setting was detected and IGRAs were carried-out. Five patients showed a complete correspondence of TST, TSPOT-TB and QFT-IT. Discordant results were observed in patients testing positive to IGRAs but negative to TST. Only 2 patients showed positive TST and negative IGRAs., Conclusion: Our study showed a poor concordance between tuberculin skin test and IGRAs, mainly in patients with a low CD4 cell count., (Copyright © 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2015
25. Suppression of pre adipocyte differentiation and promotion of adipocyte death by anti-HIV drugs.
- Author
-
Manente L, Lucariello A, Costanzo C, Viglietti R, Parrella G, Parrella R, Gargiulo M, De Luca A, Chirianni A, and Esposito V
- Subjects
- 1-Methyl-3-isobutylxanthine pharmacology, 3T3-L1 Cells drug effects, 3T3-L1 Cells metabolism, Adipocytes pathology, Alkynes, Animals, Benzoxazines pharmacology, Carbamates pharmacology, Cell Cycle drug effects, Cyclopropanes, Dexamethasone pharmacology, Enzyme Induction drug effects, Furans, HIV-Associated Lipodystrophy Syndrome chemically induced, HIV-Associated Lipodystrophy Syndrome pathology, Heme Oxygenase-1 biosynthesis, Heme Oxygenase-1 genetics, Indinavir pharmacology, Insulin pharmacology, Membrane Proteins biosynthesis, Membrane Proteins genetics, Mice, NAD(P)H Dehydrogenase (Quinone) biosynthesis, NAD(P)H Dehydrogenase (Quinone) genetics, Oxidation-Reduction, Oxidative Stress, Reactive Oxygen Species metabolism, Real-Time Polymerase Chain Reaction, Saquinavir pharmacology, Stavudine pharmacology, Sulfonamides pharmacology, Superoxide Dismutase biosynthesis, Superoxide Dismutase genetics, Superoxide Dismutase-1, Adipocytes drug effects, Adipogenesis drug effects, Anti-HIV Agents pharmacology, Apoptosis drug effects
- Abstract
In the present study, we investigated the ability of anti-HIV drugs to interfere with normal cell cycle progression and to induce oxidative stress by perturbing the redox environment. Our results provide evidence that anti-HIV drugs have a differential effect on adipocyte cell cycle and differentiation, being able to modify the response to oxidative stress through an increase of reactive oxygen species (ROS) that compromises the induction of phase-2 and antioxidant enzymes. In detail, saquinavir, efavirenz, and stavudine exert antiadipogenic influences on the model 3T3-L1 cell line, perturbing the oxidative response and inducing of apoptosis. When considered together, the effects of anti-HIV drugs on 3T3-L1 pre adipocytes are distinct but commonly antiadipogenic, thus suggesting another additional possible mechanism by which antiretroviral therapies could contribute to lipoatrophy.
- Published
- 2012
26. Comparative transcriptional profiling in HIV-infected patients using human stress arrays: clues to metabolic syndrome.
- Author
-
Esposito V, Manente L, Viglietti R, Parrella G, Parrella R, Gargiulo M, Sangiovanni V, Perna A, Baldi A, De Luca A, and Chirianni A
- Subjects
- Adipogenesis drug effects, Adipogenesis genetics, Anti-HIV Agents adverse effects, CCAAT-Enhancer-Binding Proteins metabolism, DNA, Complementary genetics, HIV Protease Inhibitors adverse effects, HIV Protease Inhibitors pharmacology, HIV-Associated Lipodystrophy Syndrome chemically induced, HIV-Associated Lipodystrophy Syndrome epidemiology, HIV-Associated Lipodystrophy Syndrome metabolism, Humans, Incidence, Metabolic Syndrome epidemiology, Metabolic Syndrome genetics, Oxidative Stress drug effects, Oxidative Stress genetics, Peroxisome Proliferator-Activated Receptors metabolism, Anti-HIV Agents pharmacology, Antiretroviral Therapy, Highly Active adverse effects, Gene Expression Profiling, HIV Infections genetics, HIV-1, Metabolic Syndrome chemically induced, Transcription, Genetic drug effects
- Abstract
Highly active antiretroviral therapy (HAART therapy) for HIV-1 infection has significantly increased the survival and quality of life of patients with this disease. However, in several epidemiological studies the onset of metabolic syndrome is a phenomenon reported to be extremely frequent. In the present study, genes involved in the molecular cascade responsible for the alteration of fat tissue and of lipid and glucose metabolism in patients with HIV-1 infection treated with antiretroviral therapy were identified. Towards this goal, hybridization using Atlas cDNA Expression Arrays allowed simultaneous monitoring of the expression levels of approximately 250 genes and identification of a panel of changes in relation to different therapeutic groups and in the presence of metabolic syndrome, with some genes being up-regulated, while others are down-regulated in the different subgroups of patients. The results of this analysis have shown a panel of transcriptional changes associated with oxidative stress mechanisms that provide a basis for further studies on understanding of mechanisms that, in vivo, are the foundation the metabolic disorders in patients with HIV infection.
- Published
- 2012
27. Safety of fosamprenavir in a cohort of HIV-1-infected patients with co-morbidities.
- Author
-
Esposito V, Chiodini P, Viglietti R, Parrella R, Parrella G, Maddaloni A, Sangiovanni V, Gargiulo M, Abrescia N, and Chirianni A
- Subjects
- Alanine Transaminase blood, Aspartate Aminotransferases blood, Blood Glucose, Carbamates therapeutic use, Cholesterol blood, Cohort Studies, Comorbidity, Female, Furans, HIV Infections complications, HIV Infections epidemiology, Hepatitis C, Chronic complications, Humans, Male, Middle Aged, Organophosphates therapeutic use, Retrospective Studies, Sulfonamides therapeutic use, Triglycerides blood, Carbamates adverse effects, HIV Infections drug therapy, HIV-1, Hypertension epidemiology, Neoplasms epidemiology, Organophosphates adverse effects, Sulfonamides adverse effects
- Abstract
Background: The hypothesis that fosamprenavir-including highly active antiretroviral therapy (HAART) regimens would be associated with few metabolic and hepatic side-effects was investigated., Patients and Methods: An observational single-arm retrospective study was set up on a cohort of 139 human immunodeficiency virus (HIV)-infected patients, followed up at A.O.R.N. Cotugno Hospital, Naples, Italy, treated with antiretroviral regimens including fosamprenavir, in order to evaluate the safety of these regimens in relationship to hepatic and metabolic side-effects, also considering co-morbidities and other risk factors., Results: Only seven patients met the criteria to reach the primary end-point (grade ≥ 3 adverse event) and none of them discontinued HAART therapy during the follow-up period. Eighty percent of the patients reached viral load <50 cp/μl at 48 weeks of observation. At the end of follow-up, no patient with fasting serum total cholesterol and/or fasting serum triglycerides above grade 3 was found, while 1 out of 114 (0.88%) cases presented aspartate transaminase and alanine transaminase ≥ grade 3 and 1 out of 114 (0.88%) cases had fasting serum glucose ≥ grade 3. One out of 137 patients developed a malignant neoplasm (0.73%) and 4 (2.92%) displayed newly diagnosed hypertension., Conclusion: Fosamprenavir-based regimens caused a low number of serious metabolic adverse events during a 48 week follow-up period, with a low incidence of co-morbidities and satisfying results in terms of viro-immunological response including for patients with already existing co-morbidities requiring other therapies.
- Published
- 2011
28. [Effect of antiretroviral therapy on carotid intima-media thickness in HIV-infected patients].
- Author
-
Ferraro S, Paolillo S, Gargiulo M, Costanzo P, Maggi P, Chirianni A, Chiariello M, and Filardi PP
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Carotid Arteries drug effects, Carotid Arteries pathology, HIV Protease Inhibitors pharmacology, HIV Protease Inhibitors therapeutic use, HIV Reverse Transcriptase antagonists & inhibitors, HIV Seropositivity drug therapy, Tunica Intima drug effects, Tunica Intima pathology, Tunica Media drug effects, Tunica Media pathology
- Abstract
Background: The introduction of highly active antiretroviral therapy reduced HIV-associated morbidity and mortality, at the cost of adverse metabolic effects that increase cardiovascular risk. The aim of this study was to evaluate the impact of exposure to protease inhibitors (PI) compared with exposure to non-nucleoside reverse transcriptase inhibitors (NNRTI) on carotid intima-media thickness (IMT) and blood flow velocity and to measure vascular involvement over a 2-year follow-up in HIV-infected patients treated with PI., Methods: Thirty-five HIV-infected patients treated with PI (group I) and 15 patients treated with NNRTI (group II) underwent epiaortic vessel ultrasonography. The same evaluation was obtained in a group of 20 healthy subjects. After 20 +/- 2 months, 22 patients of group I were re-evaluated and the follow-up data were compared with those obtained at baseline., Results: The ANOVA test showed a significant difference among the three groups for IMT and flow velocities. Bonferroni analyses showed significant differences in IMT and flow velocities in group I vs group II vs controls: IMT of the right common carotid artery was 0.742 +/- 0.135 mm in group I vs 0.642 +/- 0.131 mm in group II (p < 0.05) and 0.616 +/- 0.069 mm in controls (p = 0.002); IMT of left common carotid artery was 0.720 +/- 0.108 vs 0.659 +/- 0.066 mm (p < 0.05) and 0.640 +/- 0.081 mm (p < 0.01), respectively. There were no differences in group II vs healthy subjects. At follow-up examinations of group I, no significant differences were observed in both IMT and blood flow velocity when compared with baseline values., Conclusions: The HIV-infected patients treated with PI show earlier vascular involvement as compared to those treated with NNRTI and to healthy subjects with similar distribution of cardiovascular risk factors. However, such damage seems to have no significant progression over a 2-year follow-up in HIV-infected patients treated with PI. These data emphasize the need for follow-up studies assessing whether these changes are predictive of adverse cardiac events.
- Published
- 2009
29. A color Doppler ultrasound-based comparative study between stavudine and non-stavudine regimens in the onset of vascular lesions in HIV-1-positive patients.
- Author
-
Maggi P, Chirianni A, Lillo A, Perilli F, Gargiulo M, Esposito V, Bellacosa C, Pastore G, and Regina G
- Subjects
- Adolescent, Adult, Aged, Child, Female, HIV Seropositivity, Humans, Male, Middle Aged, Treatment Outcome, Anti-HIV Agents therapeutic use, HIV Infections complications, HIV Infections drug therapy, Stavudine therapeutic use, Ultrasonography, Doppler methods, Vascular Diseases complications, Vascular Diseases diagnostic imaging, Vascular Diseases drug therapy
- Abstract
Background: The present study aimed to investigate the role of stavudine in the onset of premature vascular lesions using an ultrasound color Doppler evaluation of the carotid vessels., Patients and Methods: A total of 266 patients were evaluated: 149 were treated with stavudine (group I) and 117 without stavudine (group II)., Results: Of the patients in group I, 41% exhibited vascular lesions vs. 26% in group II (p=0.0103). The two groups were further divided into subgroups Ia (stavudine and proteinase inhibitor, PI), Ib (stavudine and non-nucleotidic reverse transcriptase inhibitor, NNRTI), IIa (PI, without stavudine) and IIb (NNRTI without stavudine). A higher prevalence of lesions emerged in group Ia, while group IIa were at higher risk of developing vascular lesions than groups Ib and IIb., Conclusion: Although stavudine per se does not seem to determine damage of the epiaortic vessels, the association of a PI with stavudine is related to a significantly higher rate of lesions.
- Published
- 2008
30. Role of chlamydia infection in the pathogenesis of atherosclerotic plaques in HIV-1-positive patients.
- Author
-
Maggi P, Monno R, Chirianni A, Gargiulo M, Carito V, Fumarola L, Perilli F, Lillo A, Bellacosa C, Panebianco A, Epifani G, and Regina G
- Subjects
- Adult, Arteriosclerosis pathology, Case-Control Studies, Chlamydophila pneumoniae isolation & purification, Female, Humans, Male, Middle Aged, Risk Factors, Arteriosclerosis etiology, Arteriosclerosis microbiology, Chlamydia Infections complications, HIV Seropositivity, HIV-1 immunology
- Abstract
Background: Various authors have hypothesized a role of Chlamydia pneumoniae infection in the pathogenesis of atherosclerosis. To better understand the possible role of this infection in the pathogenesis of epi-aortic lesions in HIV-1-positive patients, the presence of anti-Chlamydia pneumoniae antibodies was evaluated in a group of individuals subjected to ultrasonography of the epi-aortic vessels., Patients and Methods: The presence of specific antibodies in 129 subjects was determined; 59 patients were HIV-1-positive, of whom 30 had carotid plaques and 29 were without lesions. The control group was composed of 70 subjects. All were subjected to ultrasonography of the epi-aortic vessels. IgG, IgM and IgA anti-C. pneumoniae antibodies were measured with micro-immunofluorescence and positive sera were tested for C. trachomatis and C. psittaci., Results: No subjects were positive for IgM. Both the IgA and IgG levels did not differ significantly in the three groups. The only highly significant variable was the use of protease inhibitors., Conclusion: Our data suggest that the damage to the carotid wall in HIV-1 patients was not due to C. pneumoniae.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.